January 2016

Technical, financial, existential—health information exchanges (HIEs) have been plagued by all sorts of problems. But payers want in because of value-based payment.

Two companies, two drugs for Duchenne muscular dystrophy in the expedited approval process. The stakes are high, especially for patients and their families.